Thursday, October 25, 2018 | A Comprehensive Strategy for Evaluating NGS Liquid Biopsy and Tumor Tissue Assays
This webinar will detail a comprehensive strategy that a lab has put in place to evaluate NGS oncology assays for genomic tumor profiling of plasma and tissue samples.
The growing adoption of next-generation sequencing (NGS) technologies is enabling many labs to perform NGS-based tumor profiling inhouse. Today, genomic tumor profiling can be accomplished using DNA extracted from tumor tissue samples, as well as by liquid biopsy approaches using circulating tumor DNA (ctDNA) in plasma samples. The question of what labs need to consider when choosing the right solution for their research needs is of great interest.
In this webinar, Dr. Shelly Gunn, Chief Medical Officer of ResearchDx, will present an overview of their lab’s approach to establishing optimized ctDNA and formalin-fixed, paraffin-embedded (FFPE) tissue workflows for in-house clinical research testing. Dr. Gunn’s presentation will:
The AVENIO ctDNA Analysis Kits and AVENIO Tumor Tissue Analysis Kits are for research use only, and not for use in diagnostic procedures.
When: Thursday, October 25, 2018 10:00 CET
AVENIO is a trademark of Roche.
Shelly Gunn MD, PhD, FCAP